Questions | Answers | Chief physicians (n = 502) | Deputy chief physicians (n = 356) | Attending physicians and residents (n = 163) | P-value |
---|---|---|---|---|---|
Treatment conditions | |||||
Is the price of medication acceptable? | Yes | 353 (70.3%) | 258 (72.5%) | 123 (75.5%) | 0.427 |
No | 149 (29.7%) | 98 (27.5%) | 40 (24.5%) | ||
Are drugs sufficient? | Yes | 133 (26.5%) | 79 (22.2%) | 38 (23.3) | 0.328 |
No | 369 (73.5%) | 277 (77.8%) | 125 (76.7%) | ||
What is your major drug source? | Imported | 156 (31.1%) | 132 (37.1%) | 50 (30.7%) | 0.048* |
Domestic | 274 (54.6%) | 177 (49.7%) | 78 (47.9%) | ||
Available | 72 (14.3%) | 47 (13.2%) | 35 (21.5%) | ||
What is the percentage of the advanced stage cancer in your practice? | < 40% | 153 (30.5%) | 91 (25.6%) | 56 (34.4%) | 0.226 |
40–60% | 184 (36.7%) | 140 (39.3%) | 62 (38.0%) | ||
> 60% | 165 (32.9%) | 125 (35.1%) | 45 (27.6%) | ||
What is the percentage of the first diagnosis? | < 20% | 265 (52.6%) | 182 (51.1%) | 94 (57.7%) | 0.157 |
20–40% | 134 (26.7%) | 116 (32.6%) | 41 (25.2%) | ||
> 40% | 104 (20.7%) | 58 (16.3%) | 28 (17.2%) | ||
Is the method of diagnosis enough? | Yes | 239(47.6%) | 180(50.6%) | 94(57.7%) | 0.082 |
No | 263(52.4%) | 176(49.4%) | 69(42.3%) | ||
Is your hospital able to conduct further tests to determine the nature of the liver masses? | Yes | 488(97.2%) | 344(96.6%) | 149(91.4%) | 0.003* |
No | 14(2.8%) | 12(3.4%) | 14(8.6%) | ||
Medication methods | |||||
Do you advocate traditional Chinese medicine? | Yes | 314 (62.5%) | 217 (61.0%) | 103 (63.2%) | 0.851 |
No | 188 (37.5%) | 139 (39.0%) | 60 (36.8%) | ||
What is your preferred immunotherapy drug? | PD-1 | 383 (76.3%) | 279 (78.4%) | 111 (68.1%) | 0.011* |
PD-L1 | 100 (19.9%) | 61 (17.1%) | 49 (30.1%) | ||
CTLA-4 | 19 (3.8%) | 16 (4.5%) | 3 (1.8%) | ||
How do you deal with adverse effects of targeted therapy? | Keeping the dosage and frequency | 177 (35.3%) | 124 (34.8%) | 55 (33.7%) | 0.688 |
Reducing the dosage | 268 (53.4%) | 181 (50.8%) | 84 (51.5%) | ||
Intermittent medication | 57 (11.4%) | 51 (14.3%) | 24 (14.7%) | ||
What is your preferred targeted drug? | Sorafenib | 275 (54.8%) | 205 (57.6%) | 92 (56.4%) | 0.302 |
Lenvatinib | 182 (36.3%) | 113 (31.7%) | 49 (30.1%) | ||
Second-line drugs | 45 (9.0%) | 38 (10.7%) | 22 (13.5%) | ||
Treatment strategies | |||||
What are your major considerations for prescribing? | Cost or insurance | 178 (35.5%) | 126 (35.4%) | 56 (34.4%) | 0.794 |
Effectiveness | 249 (49.6%) | 166 (46.6%) | 79 (48.5%) | ||
Availability | 75 (14.9%) | 64 (18.0%) | 28 (17.2%) | ||
What is your preferred treatment regimen? | Targeted therapy | 63(12.5%) | 31(8.7%) | 20(12.3%) | 0.264 |
Immunotherapy | 5(1.0%) | 3(0.8%) | 4(2.5%) | ||
Target therapy & Immunotherapy | 421(83.9%) | 316(88.8%) | 134(82.2%) | ||
Chemotherapy | 13(2.6%) | 6(1.7%) | 5(3.1%) | ||
Do you support the disclosure of the patients’ true conditions? | Yes | 336(66.9%) | 215(60.4%) | 81(49.7%) | <0.001* |
No | 166(33.1%) | 141(39.6%) | 82(50.3%) | ||
Who will make the final decisions on treatment? | Doctors | 89(17.7%) | 39(11.0%) | 13(8.0%) | 0.004* |
Patients | 121(24.1%) | 86(24.2) | 35(21.5%) | ||
Patients’ family | 292(58.2%) | 231(64.9%) | 115(70.6%) | ||
Is the pathological diagnosis important? | Yes | 230(45.8%) | 191(53.7%) | 98(60.1%) | 0.003* |
No | 272(54.2%) | 165(46.3%) | 65(39.9%) | ||
What is your recommended hospital when the diagnosis is vague? | Local hospitals | 61(12.2%) | 64(18.0%) | 28(17.2%) | <0.001* |
Provincial capital hospitals | 197(39.2%) | 170(47.8%) | 95(58.3%) | ||
National top hospitals | 244(48.6%) | 122(34.3%) | 40(24.5%) |